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Gene expressionst milk transmitted MoMuLV-ts1 retrovirus infection and subsequent lymphoma
development in offspring of uninfected mothers suckled by infected surrogate mothers. Additionally, we
have shown that the lymphoma development occurs as a result of viral gene integration into host genome. A
total of 146 pups from Balb/C mice were divided into 5 groups; one control and 4 experimental. All offspring
suckled from surrogate infected or control mothers, except one group of infected pups left with their
biological mothers. Thirteen of 91 infected pups developed lymphoma. Inverse-PCR, DNA cloning, and
quantitative real-time PCR (qRT-PCR) were used to study the virus integration sites (VIS) and alterations in
gene expression. VIS were randomly distributed throughout the genome. The majority of insertion sites were
found in chromosomes 10, 12 and 13. A total of 209 proviral genomic insertion sites were located with 52
intragenic and 157 intergenic sites. We have identiﬁed 29 target genes. Four genes including Tacc3, Aurka,
Gﬁ1 and Ahi1 showed the maximum upregulation of mRNA expression. These four genes can be considered
as candidate genes based on their association with cancer. Upregulation of these genes may be involved in
this type of lymphoma development. This model provides an important opportunity to gain insight into the
relationship of viral gene insertion into host genome and development of lymphoma via natural transmission
route such as breast milk.
© 2008 Elsevier Inc. All rights reserved.IntroductionDuring the current investigation, we have used the Moloney
Murine Leukemia Virus — temperature sensitive mutant (MoMuLV-
ts1) to induce lymphoma, by maternally transmitted retrovirus
infection via breast milk in mice. Our laboratory is the ﬁrst to show
the development of lymphoma among the offspring of ts1 infected
mothers. Lymphoma induction by integration of the Moloney Murine
Leukemia Virus (MoMuLV) genome into the mouse genome has been
demonstrated by a number of investigators (Hwang et al., 2002;
Johnson et al., 2005; Joosten et al., 2002; Kim et al., 2003; Lund et al.,
2002; Mikkers et al., 2002; Sorensen et al., 1996; Suzuki et al., 2002).
Induction of lymphoma by MoMuLV is a multistep process driven by
both viral and non-viral mechanisms (Fan et al., 1997; Hartley et al.,
1997). Although provirus integration is random in virus infected non-
tumor cells, it shows regional speciﬁcity in these lymphomas,
suggesting that insertional mutagenesis may play an important role
in tumor induction and progression. MoMuLV, unlike transforming
viruses, lacks oncogenes and employs mechanisms such as promoter
insertion and enhancer activation to induce tumors. MoMuLV
infection activates Rel/NF-kB transcription factor, (Pak and Faller,hakraborty).
l rights reserved.1996) which may participate in induction of lymphoma. Several other
viruses, such as human immunodeﬁciency virus 1 (HIV-1) and
cytomegalovirus, activate NF-kB (Bachelerie et al., 1991; Cherrington
and Mocarski, 1989). Existing literature shows that lymphomas
associated with MoMuLV are clonal tumors and appear four to six
months following virus inoculation. The proviral integration form of
the retrovirus is generally located near an appropriate cellular proto-
oncogene in tumor cells. Activation of the proto-oncogenes causes
pathological changes in speciﬁc cell types leading to clonal expansion
of the infected cell producing cancer (Kim et al., 2003). Targeted genes
have been shown to play an important role in oncogenesis (Neel et al.,
1981; Nusse and Varmus, 1982; Rosenberg and Jolicoeur, 1997). PCR
and RT-PCR-based methods were used by Paun et al. (2005) and by
Shin et al. (2004) for LP-BM5 and ecotropic MuLV in C57 BL/6J, AKR
and C58 mice respectively. Positions of provirus/host DNA junctions
were identiﬁed by PCR-based techniques in murine tumors using SL3-
3 retrovirus in T-cell lymphomas (Rasmussen et al., 2005). According
to Kim et al. (2003), candidate cancer genes in mouse T-cell
lymphomas induced by SL3-3 retrovirus include transcription factors,
such as Fos, Gﬁ1, Lef1, Myb, Myc, Runx3 and Sox3, all three D cyclins
and Ras signaling pathway factors, including Rras 2/TC 21, Rasgrp 1
and Cmkbr7/CC R7. Rras 2was the most frequent target with increased
expression observed in insertions as far as 57 kb from the transcribed
region. This study justiﬁed the importance of genome-based analysis
Table 1
Five groups of animals showing route of transmission, rates of infection and development of lymphoma
Group # Offspring Surrogate mother Sample size PCR analysis Lymphoma
Positive ts1 Negative ts1 # %
# % # %
Gr 1 (n=9) Ctrl → Ctrl 9 0 0.0 9 100.0 0 0.0
Gr 2 (n=46) ts1 → Ctrl 46 36 78.3 10 21.7 0 0.0
Gr 3 (n=29) ts1 → ts1 29 29 100.0 0 0.0 2 6.9
Gr 4 (n=38) Ctrl → ts1 38 37 97.4 1 2.6 6 15.8
Gr 5 (n=24) ts1 → Biological mother 24 24 100.0 0 0.0 5 20.8
Ctrl — Control (no infection).
ts1 — Infected (positive for MoMuLV-ts1).
Five groups of offspring from DMEM injected control or MoMuLV-ts1 infected mothers, left to suckle from the control or infected surrogate mothers, except group 5 which suckled
from their biological mothers. Gr 1 (control) had no infection or lymphoma. Gr 2 had 78% infection (column 5) but no lymphoma (column 8). Gr 3, 4 and 5 had almost 100% infection
rate and 6.9%, 15.8% and 20.8%, respectively, developed lymphoma (bold numbers). A total of 13 offspring (column 8) of 126 infected (column 4) developed lymphoma. Control: ctrl;
MoMuLV-ts1 infected: ts1.
Table 2
Summary of the analysis of colonies with virus insertion sites (VIS) from pups with
infection but no lymphoma (NLYM) and pups with infection and lymphoma (LYM)
Number of colonies
analyzed
Number of colonies
with inserts
Number of colonies with
speciﬁc VIS sites
N LYM 1 61 23 4
N LYM 2 50 20 13
N LYM 3 50 38 20
N LYM 4 50 28 12
LYM 1 108 75 46
LYM 2 110 61 23
LYM 3 80 26 14
LYM 4 50 19 7
LYM 5 50 35 31
LYM 6 111 43 39
Total 720 368 209
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their potential role in human cancer. Suzuki et al. (2002) identiﬁed
884 retroviral integration sites (RIS) in B-cell lymphomas in their
mouse model using retroviral tagging for gene discovery by inverse-
PCR (I-PCR), DNA sequencing and bioinformatics tool provided by
Mouse Genome Project. These authors located 36 common retroviral
integration sites (CIS) that are known or predicted to be genes
involved in human cancer or their homologs. This approach has been
extremely powerful for identiﬁcation of a large number of genes for
different diseases (Suzuki et al., 2002). Shin et al. (2004) located 62
common integration sites including 31 previously identiﬁed sites.
Seven new sites were identiﬁed in marginal zone lymphoma (MZL) of
NFS.V+ mice. They found differential patterns of gene expression and
disease progression for Gﬁ1, Sox4, Brca2, Snf1lk, Nfkb1, Pou2af1,
Prdm1, Stat6 and Blnk by using microarrays and qRT-PCR. Hansen
et al. (2000) and Li et al. (1999) identiﬁed target genes and several
candidate cancer genes. They demonstrated that genome-based
analysis of retroviral insertion sites for identiﬁcation of speciﬁc cancer
candidate genes is a highly powerful technique. Identiﬁcation of large
numbers of candidate cancer genes is possible by analysis of retroviral
common integration sites in tumors based on the mouse genome
sequence (Kim et al., 2003; Li et al., 1999; Suzuki et al., 2002).
MoMULV-ts1 is an excellent model for studying the molecular
mechanism of lymphoma development through natural transmission
of a retrovirus via breast milk to the offspring of infectedmothers, and
their progression through clinical stages. Typically 100% of mice
infected with wildtype MoMuLV develop lymphoma (Fan. 1997). In
our model, about 13–15% of offspring developed lymphoma, thus
providing an excellent control system. The pups of the same litter had
a 100% infection rate, but with or without the lymphoma. Using this
model, we have identiﬁed 29 target genes by inverse-PCR (I-PCR) for
viral integration that could be candidate genes involved in lymphoma
development. This model is interesting since no clear evidence is
available to date on breast milk transmitted virus induced lympho-
magenesis. Although Epstein-Barr virus (EBV) (Fan et al., 2005) has
been implicated in lymphoma development in HIV infected patients,
no conclusive evidence of the carcinogenicity of this virus has been
presented thus far. Non-Hodgkins lymphoma is an AIDS deﬁning
illness. However, there is no direct established relationship between
HIV infection and development of lymphoma. Although several
investigators have reported that HIV-1 integration into host cells
causing T-cell lymphoma, further studies are needed to understand
the effect of HIV on lymphoma development. For example, HIV
integration was reported within fur gene at upstream of c-fes/fps
proto-oncogene causing T-cell lymphoma (Shiramizu et al., 1994).
Additionally, integration of HIV-1 in T-lymphocytes has been shown to
cause malignant transformation leading to lymphoma (Herndier et al.,
1992). In other studies, tax gene has been shown to immortalize T-
lymphocytes and cause T-cell lymphoma by human T-cell leukemiavirus (HTLV-1) (Jeng et al., 2004 and Blattner, 1999). It must be noted
that HIV-1 infection causes considerable increase in cancer burden
through multiple mechanisms. Therefore, a retroviral model for
cancer induction needs careful investigation and our model will
help provide information regarding the relationship between retro-
viral infection and lymphomagenesis.
Results
Lymphoma development in offspring of uninfected and infected mothers
via breast milk of infected biological and surrogate mothers
Nine control pups born to control mothers (DMEM injected) were
suckled from surrogate control mothers, none of which had ts1
infection or lymphoma (Group 1). None of the 46 pups from infected
mothers developed lymphoma when suckled from uninfected
surrogate mothers (Group 2), although 78% of these pups tested
positive for ts1. Thirteen pups which developed lymphomawere from
three different experimental conditions: two of 29 pups from infected
mothers that suckled from infected surrogate mothers developed
lymphoma (Group 3). Six of 38 control pups from uninfected mothers
developed lymphomawhen theywere allowed to suckle from infected
surrogate mothers (Group 4). Five of 24 pups from infected mothers
developed lymphoma when they suckled from their ts1 infected
biological mothers (Group 5) (Table 1).
Identiﬁcation of proviral genome integration sites by inverse-PCR (I-PCR)
Spleen and lymph node tissues were used for this study in
determining viral integration sites. Tissues from uninfected pups
suckled from uninfected control mothers were used to obtain baseline
values for fold change in gene expression levels but not for
Table 3
The intragenic (a) and intergenic (b) viral integration sites and their chromosome locations
Chromosome # Intragenic
hits
RIS name Gene ID
upstream
Gene ID
downstream
1 2 5430435G22Rik Ctse Slc26a9
1 1 Traf3ip3 A130010J15Rik Hsd11b1
2 3 Tde1/Serinc3 5830472M02Rik Pkig
2 1 Ppp1r16b Actr5 2310007D09Rik
4 1 Gpr51 A630005A Samd6
4 1 170012312Rik LOC666845 LOC383991
4 1 Rgs3 4933430l17Rik Zfp618
5 1 Evi5 Gﬁ1 Rpl5
5 1 Snx8 Nudt1 Eif3s9
5 3 Ncor2 3110032G18Rik Scarb1
5 1 Cit Ccdc64 Prkab1
6 1 Tgfa Add2 2010309E21Rik
6 1 Vamp5 AF119384 Vamp8
6 1 Il17ra Jarid1a Cecr6
7 1 A930008G19Rik 23100007H09Rik 2010208k18Rik
7 1 LOC665427 6430701C03Rik Clcn4-2
9 1 2310001H13Rik Ulk4 Cck
9 1 Trak1 Ctnnb1 Cck
9 1 Ube1l Traip D330022AD01Rik
10 1 Ahi1 Pde7b Hbs1l
10 1 Al317395 BC021785 Slc16a10
10 9 Elk3 Pctk2 Lta4h
10 1 B4galnt1 4632413K17Rik C78409
11 1 Jmjd3 2600017H02Rik 2900022L05Rik
11 2 Rnf43 Gm739 Supt4h1
12 1 Cpsf2 Mjd Slc24a4
13 3 Aytl2 Mrpl36 Slc6a3
15 1 1110014D18Rik E430025E21Rik Trib1
16 2 Lpp LOC433009 5430420C16RiK
17 1 Trml2 Trml4 B430306N03Rik
19 1 Exoc6 Hhex LOC546726
19 2 Gprk5 Prdx3 BC029127
19 1 2810048G17Rik Pdcd11 LOC546729
X 1 Mid1 G53001100Rik LOC667853
Total no. of
hits
52
Chromosome # Intergenic
hits
RIS name Gene ID
upstream
Gene ID
downstream
1 2 N/A LOC624702 LOC624755
1 1 N/A Xpr1 Acbd6
1 2 N/A St8sia4 Gm1833
1 1 N/A 1700027A15Rik Tns1
1 1 N/A Pthr2 Crygf
1 1 N/A Dtymk Ing5
2 4 N/A Aurka Cstf1
2 1 N/A Stxbp1 9130404D14Rik
2 1 N/A Cd93 Nxt1
3 1 N/A Evi1 Mds1
4 1 N/A Prdm16 Arpm2
5 11 N/A Tacc3 Fgfr3
5 1 N/A BC003324 6330548G22Rik
5 2 N/A Actb Fscn1
6 1 N/A Vamp5 Vamp8
7 8 N/A Ccnd1 Tpcn2
7 1 N/A Josd2 2310044H10Rik
7 1 N/A Furin Blm
8 2 N/A LOC244558 LOC824855
8 2 N/A Zfp42 Adam26b
8 1 N/A Irf8 Foxf1a
8 1 N/A Irf2bp2 A630001012Rik
9 1 N/A D630044F24Rik LOC628947
9 1 N/A Ap1m2 Slc44a2
9 1 N/A Uaca Tle3
9 1 N/A Rab11a LOC665584
10 1 N/A Ifng Dyrk2
11 2 N/A Bcl11a LOC628476
11 2 N/A Canx LOC622343
11 1 N/A Il5 Irf1
11 1 N/A Prpsap1 Sphk1
11 1 N/A Sfrs2 2600014M03Rik
12 35 N/A LOC674120 LOC67121
12 1 N/A Trib2 Lpin1
12 1 N/A LOC627607 6430527G18Rik
Table 3 (continued)
Chromosome # Intragenic
hits
RIS name Gene ID
upstream
Gene ID
downstream
12 2 N/A Dus4l Gpr22
13 1 N/A Elov12 LOC268650
13 39 N/A Dusp22 Irf4
13 1 N/A Fbp1 2010111l01Rik
13 1 N/A Ell2 Glrx
14 1 N/A Olfr750/GA Ang1
14 1 N/A Extl3 Fzd3
14 1 N/A Slc25a30 Tpt1
15 2 N/A LOC432956/
A1bg
Myc
16 2 N/A Cldn5 LOC622795
16 4 N/A Sept5 Cldn5
17 1 N/A Foxp4 1700067P10Rik
19 1 N/A 5033414D02Rik Cd274
19 1 N/A 2700046G09Rik Minpp1
X 1 N/A Hcfc1 Irak1
X 1 N/A Sat1 Acot9
X 1 N/A Apln Xpnpep2
Total no. of
hits
157
For intergenic insertion sites, the locations of upstream and downstream genes have
been included in column 1 and column 2 R1s: Retrovirus insertion sites.
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lymphoma (LYM) and pups with no lymphoma (N LYM) were used for
identiﬁcation of viral integration sites. Of 720 colonies screened, 368
were white colonies indicating the insertion of viral genome into the
murine genome and applied towards further analysis. Of these 368
colonies 209 proviral genomic insertion sites were found (Table 2).
Fifty-two were intragenic and 157 were intergenic sites with over 90
unique intra and intergenic combined viral integration sites identiﬁed
in mouse genome (Table 3). The maximum number of insertion sites
(N10) were found in chromosomes 1, 2, 5, 7, 10, 11, 12 and 13, with the
most on chromosomes 10, 12 and 13 with 26, 32 and 45 insertions,
respectively (Fig. 1). Interestingly, of all 45 inserts in chromosome 13,
39 were at the same location from one animal and none of the animals
showed viral inserts in 18 or Y chromosomes (Fig. 1).
The mRNA expression of candidate genes in spleens of control mice and
mice with lymphoma
Twenty-nine genes were selected for mRNA analysis by examining
the effect of viral integration on their expression level based on 1)
their proximity to speciﬁc genes (within 100 kb); 2) listing in
Retroviral Tagged Cancer Gene Database (http://RTCGD.ncifcrf.gov)
for genes associated with cancer in relation to retroviral insertions; 3)
their association with cancer development. The change in mRNA
expression has been depicted in Table 4a and 4b and summarized in
Fig. 2. The expression values of 29 genes examined included 11
candidate genes with intragenic VIS (viral integration site) (Table 4a)
and 18 candidate genes with intergenic VIS (Table 4b).
mRNA expression levels for genes interrupted by VIS (intragenic)
or adjacent to VIS (intergenic) were examined inmice. The fold change
of mRNA expression level compared to control group ranged from 0.10
for Ifng to 19.48 for Gﬁ1 (Table 4a — clear boxes). The mRNA
expression of Tacc3 and Aurka genes with intergenic VIS was found to
undergo the most upregulation with averages of 9.2 and 2-fold
increases in mRNA expression respectively compared to controls. Gﬁ1
showed the highest levels of mRNA expression with a 19.48-fold
increase in LYM1. Among other animals of this group (LYM), an
average of 7.1-fold upregulation was noted compared to the control
group. Gﬁ1may be a marker of clinical signiﬁcance because when the
value of LYM1 (19.48), an outlier, was removed the standard deviation
changed from borderline signiﬁcance at pb0.06 to 0.002 (signiﬁcant).
Ahi1 with intragenic VIS also showed signiﬁcant increases in mRNA
Fig. 1. This is a graphical representation, showing the MoMuLV-ts1 insertion sites on mouse chromosomes. This is a representative summary of the insertion sites and does not
include all insertions in each chromosome. All animals showed the ts1 viral genome insertion sites (VIS) on their chromosomes. Maximum number of insertions were found on
chromosomes 10 (26), 12 (32) and 13 (45). Moderate number of insertions were found on chromosomes 1 (10), 2 (13), 5 (18), 7 (13), and 11 (11). Chromosomes 18 and Y did not have
any VIS in any of the animals. One mouse (LYM6) had 39 hits on chromosome 13.
103J. Chakraborty et al. / Virology 377 (2008) 100–109expression levels with an average of 3.8-fold upregulation compared
to the control mice. The mRNA expression showed a 3.4-fold
upregulation in LYM1, a 4.5-fold increase in LYM5 and a 7.8-fold
increases in LYM6. All samples from the lymphoma group for Tacc3
showed a range of 2.7-fold to 17.4-fold increases in expression when
compared to control group. LYM5 showed 17.4-fold increase and LYM6
showed 16.1-fold increase. Similarly, a 2.59-fold upregulation of
mRNA for Aurka in LYM5 was observed. Other members of the same
lymphoma group showed increases of Aurka ranging from 1.08 to 2.2-
fold compared to the control group. Table 5 shows the detail
descriptions of these 29 genes, the insertion sites, mouse and
human chromosome location and gene functions.
Discussion
Although extensive investigations have been carried out on
development of lymphoma using Moloney Murine Leukemia Virus
(MoMuLV), so far no study is available on MoMuLV-ts1 (temperature
sensitive) virus causing lymphoma among offspring of ts1 infected
females. Speciﬁcally, available literature does not address viral
transmission causing lymphoma via breast milk from biological or
surrogate infected mothers to the offspring. In our previous
investigation we have reported that breast milk is a major source of
ts1 infection among offspring of BALB/c mice (Duggan et al., 2004;
Duggan et al., 2006). Transmission of retrovirus via breast milk is
important, since transmission of HIV through breast milk is a major
source of infection for mother-to-child transmission (MTCT) in
humans (De Cock et al., 2000). Although Naarding et al. (2005)
reported the beneﬁcial effect of Lewis X (Lex), a sugar epitope in
human breast milk and proposed that binding of Lex to DC-SIGN may
reduce the HIV transmission to the infants breast fed by infected
mothers, there is no doubt that breastfeeding is the major route of HIV
transmission to babies of mothers with HIV infection (Coutsoudiset al., 2004). More work is needed regarding how speciﬁc molecules,
such as Lex in breast milk can be used to deter the entry of pathogenic
microorganisms into the cells. Many studies have shown that once a
virus such as EBV enters the cell and the viral genes insert into the host
DNA, the host genome becomes altered leading to malignancies (Fan
et al., 2005; J. Li et al., 1999; Liao et al., 1995; Scheijen et al., 1997; Shin
et al., 2004). Many of these genes produce proteins which are
responsible for causing various types of cancer. In this report, we
have shown that the insertion of ts1 viral genome into the infected pups
is associated with lymphoma. MoMuLV typically induces T-cell
lymphoma in 100% of the infected mice with a mean latency period
of 3–4months (Fan,1997). The phenotypes of the tumor cells are T-cells
with CD4−/CD8−; CD4+/CD8−; CD4+/CD8+ or CD4−/CD8+. According to
Fan (1997), the role of activated proto-oncogenes for tumorigenesis is a
multistep process, similar to humans and important insight can be
obtained from the MoMuLV studies.
We have observed distribution of VIS throughout the entire mouse
genomewith no preferred sites except one on chromosome 13with 39
hits in LYM6 mouse. This suggests that viral integration into the
mouse genome is random, similar to that reported for the HIV
integration into the human genome (Lewinski et al., 2006). Only two
VIS out of nearly 90 were identiﬁed in both groups, i.e. mice with
lymphoma and mice without lymphoma, suggesting that these two
groups may be distinct and that some VIS are not relevant in the
development of lymphomawhile other VIS are involved in lymphoma
development. This suggests that lymphoma development is a random
event, developing only when certain sites were targeted for viral
genome integration. This ﬁts well with the hypothesis that viral
integration will lead to lymphoma development only when it occurs
in areas near genes related to lymphoma development. Several genes
may be especially good candidates for lymphoma development.
Expression patterns on Tacc3 and Gﬁ1 genes were similar in mice
with lymphoma revealing upregulation for these genes, though to
Table 4a
Intragenic viral integration sites (VIS)
Table 4a
Intragenic Viral Integration Sites (VIS)
The table shows the increase in gene expression by mRNA quantitation by using comparative ddCT method. The effects of viral integration sites (VIS) in two groups of experimental
animals were studied in comparison to the control animals. These two experimental groups included animals with infection but no lymphoma (NLYM) and animals with infection
and lymphoma (LYM).
SEM: Standard error of the mean. Shaded boxes show the genes with signiﬁcant change in expression levels.
This table shows the effect of intragenic VIS. Signiﬁcant increase of mRNA expression of one gene, i.e., Ahi1 was observed in animals with lymphoma (LYM). None of the other genes
showed signiﬁcant alteration.
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an exaggerated response in expression rather than low or no response
to the stimuli showing the importance of this gene in this model.
These genes might be in the same pathway leading to lymphoma
development in these mice and thus have the same molecular
mechanisms for lymphoma development. The same patterns of
change in expression for these two genes were also observed in one
mouse without lymphoma, N LYM1 suggesting that this mouse might
have developed lymphoma if allowed to live longer. The mRNA
expression fold increases for gene Irf4 in N LYM1 and N LYM4 and Gﬁ1
in N LYM1 and N LYM3 in the infected but no lymphoma group
compared to the control group may indicate the onset of lymphoma
development in these 3 mice before overt clinical manifestations.
Although it is possible that we have missed VIS in these mice with
this assay, their similar expression patterns compared to that of mice
where the VIS were found, suggest that these genes may be in-
volved in some way in the molecular mechanism for lymphoma
development.
The change in mRNA expression levels compared to the control
group observed for these genes may be due to the VIS and may
contribute, in part, to the lymphoma development observed in these
mice. This argument is strengthened by the fact that other mice
developing lymphoma showed similar patterns of change of mRNA
expression of these genes compared to the controls. All other genes
tested for mRNA expression levels both with intergenic and intragenic
VIS showed unremarkable levels of expression compared to controls
at this time. Expression levels tested in the ts1 infected no lymphoma
(N LYM) group were also unremarkable in most part except for gene
Irf4 with intergenic VIS. Irf4 mRNA gene expression showed 1.5 and1.7-fold increases in N LYM1 and N LYM4, respectively. Gﬁ1 mRNA
expression was also upregulated in the infected but no lymphoma (N
LYM) group by 3.2-fold and 2.8-fold for N LYM1 and N LYM3
respectively, compared to the control group. It would be interesting
to see if this mouse might have developed lymphoma if the end time
point was set longer. Other genes such as Irf4 and Ccnd1 showed
upregulation in only one of the mice with lymphoma. The molecular
mechanisms for lymphoma development in these mice may be
different compared to the other groups that showed similar patterns
of change in their expression. Alternatively a given gene product
might be upstream of the pathway showing no change in its
expression. Other genes located downstream in the same pathway
changed by other VIS might show changes in their expression.
Of the 29 target genes we have identiﬁed during this study,
transforming acidic coiled-coil protein 3 (Tacc3) gene showed an over
9-fold increase in mRNA expression compared to controls. Over-
expression of Tacc3 was related to progression of non-small cell lung
cancer (NSCLC) in humans (Jung et al., 2006). Tacc3 proteins have also
been shown to contribute to breast, prostate, multiple myeloma and
ovarian cancer (Dhanasekaran et al., 2001; Lauffart et al., 2005; Still
et al., 1999a,b). Jung et al. (2006) recognized that both absence and
overexpression of Tacc3 may contribute to cancer production. These
investigators proposed that Tacc3 may be important for cancer
progression rather than the cause for cancer production. In our
study overexpression of Tacc3 may be contributing to progression of
lymphoma. Note that in the no lymphoma (NLYMP) group, no
signiﬁcant increase in Tacc3 mRNA expression was observed,
suggesting that its function was for cancer progression and not
production. In this group, the lymphoma had not yet been produced,
Table 4b
Intergenic Viral Integration Sitesi
The table shows the increase in gene expression by mRNA quantitation by using comparative ddCT method. The effects of viral integration sites (VIS) in two groups of experimental
animals were studied in comparison to the control animals. These two experimental groups included animals with infection but no lymphoma (NLYM) and animals with infection
and lymphoma (LYM).
SEM: Standard error of the mean. Shaded boxes show the genes with signiﬁcant change in expression levels. Clear boxes show the highest (Gﬁ1) and the lowest (Ifng) levels of fold
changes in mRNA expression.
This table shows the effect of intergenic VIS on mRNA expression of several genes, including Tacc3, Aurka and Vamp8. Tacc3 and Aurka show signiﬁcant upregulation, while Vamp8
showed signiﬁcant downregulation. Tacc3 and Aurka were affected in LYM group only, while Vamp8 was downregulated in both LYM and NLYM groups.
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i.e. Tacc1, Tacc2 and Tacc3 are components of the centrosomal spindle
involved in microtubule stabilization and hematopoietic develop-
ment. Tacc3 interacts with nuclear transcription factors (Piekorz et al.,
2002; Still et al., 2004). Deﬁciency of Tacc3 leads to P53 mediated
apoptosis. Therefore, overexpression of Tacc3 as it has been observed
in our mice may be causing inhibition of apoptosis thus leading to
lymphoma.
The other genewith higher than a 2-fold increase inmRNA activity is
Aurora kinase A (Aurka). Overexpression of Aurka mRNA has been
associatedwith a number of cancers including head and neck squamous
cell carcinoma, esophageal squamous cell carcinoma, glioma, pancreatic
cancer, hepatocellular carcinoma and bladder cancer (Jeng et al., 2004;
Klein et al., 2004; Li et al., 2003; Reiter et al., 2006; Sen et al., 2002;
Tanaka et al., 2005; Tonget al., 2004). Abnormal centrosomeand spindle
formation due to increased AurkamRNA expression has been reported
to promote tumor progression (Reiter et al., 2006) and Aurka inhibitors
have been proposed for cancer treatment (Andrews, 2005). Upregula-
tion of Aurka in breast milk mediated lymphoma in our mouse model
has a good potential for testing the potential of Aurka inhibitors, which
may be applied for therapeutic purposes.
Abelson helper integration site-1 (Ahi1) gene encodes a family of
proteins involved in leukemogenesis (Jiang et al., 2004). Although
Ahi1 mRNA expression has been proposed to contribute to the
development of human leukemia (Jiang et al., 2004), possibly a
different gene is involved in the process of lymphogenesis (Kim et al.,
2003). The intragenic location of our VIS in Ahi1 makes it quite
interesting to understand the interactions of nearby genes at this
location for lymphoma. Since the function of Ahi1 protein has not yetbeen well established, it seems logical to speculate that this protein
may be involved in the signal transduction pathway. Our model
provides the opportunity to study it further regarding whether an
increase in Ahi1 mRNA expression is involved in the development of
lymphoma or its progression.
Although retroviral integration into the host genome of a mouse
model has been very informative regarding how genomic alteration
causes diseases, the process is not the same as observed in human
retroviral integration (Lewinski et al., 2006). For example, HIV's most
preferred site of integration is in the active transcription units while
murine leukemia virus (MLV) integration occurs near the transcription
start sites and CpG islands. HIV can integrate at any time of the cell
cycle, while MLV can integrate only after mitosis (Lewinski et al.,
2006). Using a MLV/HIV hybrid, Lewinski et al. (2006) showed distinct
favored viral integration in HIV versus MLV. They concluded that viral
integrase (IN) is the factor which determines the site of choice of
integration. Therefore, further work is needed to understand the
similarities and differences between the genomic involvements of
murine versus HIV causing malignancy. Our MoMuLV-ts1 model
provides an important system for this study of the viral gene
integration and its relationship to lymphoma development, caused
by natural transmission via breast milk.
Materials and methods
Virus culture and assay
The MoMuLV-ts1 viral stock, TB cells (Thymus-Bone marrow) for
viral culture and 15F cells for viral assay were kindly provided by Dr. P.
Fig. 2. Graphical representation of the mRNA expression of 29 genes, summarized from Table 3, using comparable ddCT method. Ahi1, Tacc3 and Aurka showed signiﬁcant increase in
mRNA expression.
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Smithville, Texas. Brieﬂy, the ts1 virus was grown in TB cells. TB cells
were cultured in Dulbecco Modiﬁed Eagle Medium (DMEM) with 6%
fetal calf serum, 4% newborn calf serum and 1% penicillin/streptomy-
cin at 37 °C until 70–80% conﬂuency. TB cells were then treated with
Polybrene in DMEM containing 3% heat inactivated newborn calf
serum and 1% penicillin/streptomycin. 1×106 focus forming units
(ffu)/ml of ts1 virus was added to TB cells. The cell suspensionwith the
virus was incubated at 34 °C for 40 min. After that, the cells were
cultured in fresh DMEM at 34 °C for 3 days or until 70–80% conﬂuency.
Culture media containing viral particles was removed and ﬁltered
through a 0.45 µm ﬁlter and stored in 1 ml aliquots at −80 °C
(Chakraborty et al., 2003).
The 15F cells were grown for viral assay by the same method
described above for the TB cells. 9.6×106 cells/ml were plated onto
60mmculture plates in Polybrene. Serial dilutionsof 0.2mlviral stock to
be assayed were added to the 24 well plates. Next, 0.5 ml of
corresponding viral dilutions were transferred to respective 60 mm
plates and incubated at 34 °C for 40min.Mediumwas aspirated and the
cellswere incubated in freshDMEM for 3days at 34 °C. FreshDMEMwas
added after 3 days and cells were again incubated for 2–3 more days at
34 °C and ffu on theplateswere counted. Aﬁnal viral titer of 4.0×106 ffu/
ml was obtained for the viral stock (Chakraborty et al., 2003).
All experiments involving mice were carried out according to an
approved IACUC protocol and under the direct supervision of trained
personnel of the Department of Laboratory Animal Medicine at the
College of Medicine, Health Science Campus, University of Toledo, OH.
Lymphoma induction in the offspring of ts1 infected mothers
Eighteen timed pregnant BALB/c female mice were purchased from
Charles River Co., (Wilmington, Maine). Two to three days after arrival,
the 18 females delivered 68 pups at our animal facility. Seventy-two
hours after birth, 54 (33 females and 21 males) of these 68 pups were
injected intraperitoneally (ip) with 0.1 ml of 4.0×106 ffu/ml of ts1 virusand designated as infected (experimental) group. The other 14
(11 females and 3 males) pups were injected with 0.1 ml DMEM only,
producing anuninfected (control) group. All pupswere allowed to reach
adulthood. Eleven extra males were purchased from Charles River
Laboratories for mating purpose. All femaleswere allowed tomatewith
control males. The experimental males were euthanized. Thirty-three
experimental females produced 99 pups and 11 control females
produced 47 pups. Within 6 to 12 h after birth, offspring were allowed
to suckle from either control or ts1 infected mothers. These 146 pups
were divided into 5 groups (see Table 1). Group 1 had 9 pups from
control mothers, which suckled from control surrogate mothers. Forty-
six group 2 experimental pups suckled from surrogate control mothers.
Twenty-nine group 3 experimental pups suckled from ts-1 infected
surrogate mothers. Thirty-eight group 4 control pups suckled from ts1
infected surrogate mothers. Twenty-four group 5 experimental pups
suckled from their infected biological mothers. PCR were performed
using tissue samples from all experimental and control pups to identify
ts1 viral genome to determine the infection. Thirteen of 91 pups from
groups 3, 4 and 5 developed lymphoma. The lymphoma was scored by
using the weight data of the spleen and visual estimation of the lymph
nodes (mesenteric) and thymus (photographs published in our previous
paper, Duggan et al. (2004). An increase of 5 to 25-fold of the weight of
the spleenswas recorded as splenomegaly and increase in the size of the
lymph nodes and thymus in combination with the increase in spleen
weight was considered as the indication of lymphoma. Tissues from the
spleens and lymph nodeswere collected from all animals for analyses of
viral genome integration sites. However for the current study, only
tissues from spleens were used. Tissues from 5 control animals, 4 with
infection but no lymphoma and 6 with infection and lymphoma were
used for I-PCR and mRNA expression studies.
Inverse-PCR (I-PCR) and DNA cloning
Spleens and lymph nodes from infected mice that developed
lymphoma and from infected mice that did not develop lymphoma
Table 5
Summary of twenty-nine genes analyzed and their functions
Gene
symbol
Gene name Mouse
chr no.
No.
hits
Human
homolog
Intragenic/
intergenic
VIS
Function Accession
Elk3 ETS oncogene family 10C-D1 9 12q23 Intragenic Repressor of heme oxygenase 1 (HO-1) gene transcription involved in
cell migration
NM_013508.1
Dusp22
and Irf4
Dual speciﬁcity phosphatase
22 and Interferon regulatory
factor 4
13A3 39 6p25 Intergenic Dusp22 is a positive regulator of the JNK pathway.
IRF4 is central in protecting CD4(+) cells against proapoptotic stimuli
NM_0010379
(Dusp22) and
NM_013674.1 (Irf4)
Ncor2 Nuclear receptor co-repressor
2
5F 3 12q24 Intragenic NCoR/SMRT-interacting domain transforms AML1-ETO into a potent
leukemogenic protein
NM_011424.1
Ahi1 Abelson helper integration site 10 A3 1 6q23.3 Intragenic Ahi-1/AHI-1 express in primitive hematopoietic cells BC055400
Evi5 and
Gﬁ1
Ecotropic viral integration site
5 and growth factor
independent 1
5F 1 1p22 Intragenic Evi5 is a common site for retroviral integration into T-cell lymphomas.
Gﬁ1bwas found to be upregulated in early stages of B-cell and in a subset
of early T-cell development
NM_007964.1 (Evi5)
and NM_010278.1
(Gﬁ1)
Ccnd1 Cyclin D1 7F5 8 11q13 Intergenic Cyclin D1 upregulation in intestinal neoplasia is important for tumor
progression rather than initiation. Contribute to oncogene in malignancy
NM_007631.1
Tde1
(Serinc3)
Tumor differentially expressed
protein 1 (serine incorporator
3)
2H3 3 20q13 Intragenic Inhibits apoptosis and stimulates tumorigenesis NM_012032.2
Aurka Aurora kinase A 2H3 4 20q13 Intergenic Overexpression promotes cell proliferation and inhibits apoptosis NM_011497.2
Tgfa Transforming growth factor
alpha
6D1 1 2p13 Intragenic Tumor-associated endothelial cells. TGF-alpha inhibits apoptosis in
mouse blastocysts
NM_031199.1
Tacc3 Transforming acidic coiled-
coil containing protein 3
5B3 11 4p16 Intergenic Role in hematopoietic stem cell function and interface with p53-
regulated apoptosis. Stabilizes microtubules and contributes to cancer
NM_11524.2
Prdm16 PR domain containing 16 4E2 1 1p36 Intergenic Aberrant expression associated with hypomethylation in adult T-cell
leukemia cells
NM_027504.2
Bcl11a B-cell CLL/lymphoma 11A
(zinc ﬁnger Protein)
11A3 2 2p16 Intergenic Bcl11a is essential for postnatal development and normal lymphopoiesis. NM_016707.1
Ppp1r16B Protein phosphatase 1,
Regulatory (inhibitor) subunit
16B
2H1 1 20q11.23 Intragenic mRNA is located in cell bodies and dendrites of neurons in four distinct
regions of the brain
NM_153089.2
Rgs3 Regulator of G-protein
signaling 3
4B3 1 9q32 Intragenic Induces heat shock response element (HSE)-dependent gene
transcription
NM_019492.1
Cit Citron kinase 5F 1 12q24 Intragenic Functions in the control of G(2)/M transition in the hepatocyte cell cycle NM_007708.2
Il17ra Interleukin 17 receptor A 6 F1 1 22q11 Intragenic May belong to a novel growth-receptor like molecule with capability to
support cellular mitogenesis
NM_008359.1
Mid1 Midline 1 X F5 1 Xp22 Intragenic X-linked polydactyly (Xpl) and Patchy-fur (Paf) mutant mice NM_010797.1
Evi1 Ecotropic viral integration site
1
3 A3 1 3q24-
q28
Intergenic Promotes cell proliferation. Evi1 directly binds to GATA-2 promoter as an
enhancer
NM_007963.1
Zfp42 Zinc ﬁnger protein 42 8 A4 2 4q35.2 Intergenic Embryonic stem cell marker and pluripotent stem cell marker XM_284454.5
Irf2bp2 Interferon egulatory factor 2
binding protein 2
8 E2 1 1q42.3 Intergenic No gene reference into function XM_284454.5
Ifng Interferon gamma 10 D2 1 12q14 Intergenic Participates in death of dopaminergic neurons; protection against
infection
NM_008337.1
Il5 and
Irf1
Interleukin 5/interferon
regulatory factor 1
11 A5/
B1-11
B1.3
1 5q31.1 Intergenic Eosinophils on the development and mammary gland, uterus and ovary
function. Mice lacking Irf1 develop CD30+ lymphoproliferative disease
NM_010558.1 (Il5)
and NM_008390.1
(Irf1)
Cldn5 Claudin-5 16 A3 2 22q11.21 Intergenic Claudin-5 is speciﬁcally altered in utrophin/dystrophin-deﬁcient (double
knockout), dko hearts
NM_013805.2
(Cldn5)
Vamp8 Vesicle-associated membrane
protein 8
6 C1 1 2p12-
p11.2
Intergenic VAMP-8 is required for release from dense core granules, alpha granules,
and lysosomes. Regulates exocytosis of pancreatic acinar cells
NM_016794.2
Myc Myelocytomatosis oncogene 15 D2-
D3
2 8q24.21 Intergenic Required for development of B but not pre-B cell lymphomas from cmyc
overexpressing tumor progenitors. Myc is required for a normal
hypertrophic response
NM_010849.4
Cd274 CD 274 antigen; programmed
cell death 1 ligand 1
19 C2 1 9p24 Intergenic Also known as B7-H1; PD-L1; Pdcd1l1; Pdcd1lg1. Interaction crucially
controls the effector differentiation of autoreactive T cells to maintain
self-tolerance
NM_021893.2
The table summarizes the 29 genes studied including their symbols, gene name, VIS location on mouse chromosomes, no. of hits on mouse chromosomes (column 4), human
homolog, relative position of VIS to gene, gene function and their accession numbers.
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genomic DNA was extracted from the tissues using Qiagen Genomic
DNA Puriﬁcation kit (Qiagen, Valencia, CA.), digested with BamH1,
puriﬁed and ligated using T4 ligase for I-PCR (Li et al., 1999). Primary
PCR was performed using a set of inverse primers [forward 1AF: CAG
ACA CAG ATA AGT TGC TGG CCA G (211–235) and reverse 1AR: AAG
ACG CTT GGA GAT TTG GTT AGA G (1872–1896) designed from
MoMuLV ts1 sequence at the 5′end products of BamH1 digest.
Numbers in the parenthesis indicate positions of bases on MoMuLV
ts1 sequence (Mouse Genome Database). The solution consisted of
20 pmol each for the inverse primers, 2 μl DNA template, 500 μMdNTPs, 1.3 U of Expand Long Template Polymerase and 5 μl Expand
Buffer System 3 (Roche Diagnostics Corp., Indianapolis, IN) and the
volume was brought to 50 μl with distilled water. Thermal cycling
conditions were as follows: 94 °C for 2 min followed by 10 cycles of
94 °C for 10 s, 55 °C for 30 s and 68 °C for 10 min; 25 cycles of 94 °C for
10 s, 55 °C for 30 s and 68 °C for 10 min (auto-extension 20 sec per
cycle) followed by a ﬁnal extension at 68 °C for 10 min. The secondary
PCR reaction was performed using primary PCR product as template
and using the same parameters as in primary PCR except with nested
(secondary) primers in place of primary primers [forward 2AF: AGA
CCA CGA TTC GGA TGC AAA CAG (61–84) and reverse 2AR: GAG AGA
108 J. Chakraborty et al. / Virology 377 (2008) 100–109TGAGCA AGC TAT TGG CCA C (2035–2059)]. PCR products were run on
a gel, bands were cut out, puriﬁed and cloned using TOPO TA cloning
kit (Invitrogen, Calsbad, CA) following the manufacturer's instruc-
tions. Colonies with viral inserts were identiﬁed and analyzed (see
Table 2). PCR products cloned ranged from 800 b to 2 kb, which was
expected to contain approximately 500 to 1800 bases of host genomic
sequence. Colonies were selected and puriﬁed with Qiagen Miniprep
kit (Qiagen, Valencia, CA) and sequenced at MWG-Biotech (MWG-
Biotech Inc., High Point, NC).
Quantitative reverse transcriptase-PCR (qRT-PCR)
The quantitative real-time RT-PCR technique was used to examine
differential expression of selected candidate genes. First-strand cDNAs
were reverse transcribed from total RNA (5 µg/reaction) using Oligo
(dT)20 as primers and SuperScript III (Invitrogen). Gene-speciﬁc primers
were designed using Primer Express software (version 1.5; Applied
Biosystems ABI, Foster City, CA) to amplify 75–100 bp PCR products.
Expression ofGAPDH, a “house keeping” genewas used to normalize the
data. qRT-PCR was performed essentially as described by Lee et al.
(2005) using the iCycler thermal cycling instrument and MyiQ Single-
Color real-time PCR Detection System software (BioRad, Hercules, CA).
Speciﬁcally, real-timePCRwasperformedon three replicates per sample
using IQ SYBR Green Supermix kit (BioRad, Hercules, CA) on 5 µl of
template cDNA of varying dilutions with 1 µl of gene-speciﬁc 3′ and 5′
primermixtures (2.5 µM solution) optimized for a given primer pair per
25 µl reaction. The reaction mixture contained 12.5 µl of 2× master mix
(100 mM KCl, 40 mM Tris–HCl, pH 8.4, 6 mM MgCl2, 0.4 mM dNTPs,
50 units/ml iTaq DNA polymerase, 20 nMSYBRGreen (BioRad, Hercules,
CA)), 12.5 µl of cDNA at appropriate dilutions plus primer mixtures and
distilled H2O, run on the following thermocycler programs: 95 °C for
3 min followed by 40 cycles of 95 °C for 30 s, 60 °C for 30 s 0.5 °C
increments starting at 55 °C for 80 cycles. Melt-curve analysis was
performed immediately after ampliﬁcation to conﬁrm ampliﬁcation of a
single PCR product. “No-template” controls were included to ensure
ampliﬁcation speciﬁcity. RNA expression levels were calculated for each
geneusing comparative ddCtmethodusinghouse keeping gene, GAPDH
expression levels. Gene expressions are presented as relative values and
expressed as the “fold change”.
All statistical analysis was performed by using Statistical Package
for the Social Sciences (SPSS) software. Student's t-test was used to
test the equivalence of mean gene expression between control and ts1
infected no lymphoma (N LYM) or ts1 infected with lymphoma (LYM)
development. A p value of b0.05 was used to indicate a statistically
signiﬁcant difference.
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